Form 4: Pacific Biosciences Executive Acquires Stock Options and Restricted Stock Units
SEC Form 4
Mark Van Oene, Chief Operating Officer of Pacific Biosciences, reports acquisition of stock options and restricted stock units.
Summary
- Mark Van Oene, Chief Operating Officer of Pacific Biosciences, filed a Form 4 detailing changes in beneficial ownership.
- On March 19, 2025, Van Oene acquired 449,176 Restricted Stock Units (RSUs) at a price of $0.
- These RSUs will vest in equal annual installments on February 15 of each of 2026 and 2027, contingent upon continued service.
- Also on March 19, 2025, Van Oene acquired options to purchase 898,352 shares of common stock at an exercise price of $1.25.
- These options vest in 24 equal monthly installments beginning on March 15, 2025, also contingent upon continued service.
- Following these transactions, Van Oene directly owns 1,946,871 shares of common stock and options for 898,352 shares.
- The options expire on March 19, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and indicates confidence in the executive and the company's future performance. There are no red flags or negative indicators in the filing.
Positives
- The acquisition of RSUs and stock options aligns the executive's interests with those of the shareholders.
- The vesting schedules incentivize continued service and contribution to the company's success.
Industry Context
Stock options and RSU grants are common practice in the biotech industry to attract and retain key executives, aligning their compensation with company performance and shareholder value.
Comparison to Industry Standards
- Executive compensation packages in the biotech industry often include a mix of salary, stock options, and restricted stock units.
- Companies like Illumina (ILMN) and Thermo Fisher Scientific (TMO) also utilize similar equity-based compensation strategies to incentivize their leadership teams.
- The vesting schedules and exercise prices are generally structured to reward long-term value creation.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with long-term value creation.
- Employees may see this as a positive sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/15/2025 | Options vest in 24 equal monthly installments beginning on this date. |
| 03/19/2025 | Date of transaction for both RSUs and stock options. |
| 03/21/2025 | Date of signature on the Form 4 filing. |
| 02/15/2026 | First annual installment vesting date for RSUs. |
| 02/15/2027 | Second annual installment vesting date for RSUs. |
| 03/19/2035 | Expiration date for the stock options. |
Keywords
Form 4, Pacific Biosciences, PACB, Beneficial Ownership, Stock Options, Restricted Stock Units, RSU, Executive Compensation, Mark Van Oene, COO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.